Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | City of Hope | 20 |
| 2 | University of California, San Diego | 16 |
| 3 | University of California Berkeley | 13 |
| 4 | Mallinckrodt Inc | 10 |
| 5 | Verastem Inc | 10 |
| 6 | Harpoon Therapeutics Inc | 9 |
| 7 | Bayer AG | 8 |
| 8 | Mallinckrodt LLC | 8 |
| 9 | Merck Sharp & Dohme LLC | 8 |
| 10 | Genentech Inc | 6 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 305 |
| 2 | A61P | Therapeutic activity (drug indications) | 270 |
| 3 | C07K | Peptides | 101 |
| 4 | C07D | Heterocyclic compounds | 85 |
| 5 | C12N | Microorganisms, enzymes | 48 |
| 6 | G01N | Investigating / analysing materials | 38 |
| 7 | C12Q | Measuring/testing involving enzymes | 30 |
| 8 | A61N | 17 | |
| 9 | Y02A | Climate change adaptation | 16 |
| 10 | A61B | 15 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Photodynamic Therapy Research Studies | 11 |
| 2 | Advancements in Transdermal Drug Delivery | 2 |
| 3 | Chemical Synthesis and Analysis | 1 |
| 4 | Extracellular vesicles in disease | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | François Guillemin | Centre de Recherche en Automatique de Nancy | 29 |
| 2 | Colin Hopper | University College London | 26 |
| 3 | Alfred Fahr | Friedrich Schiller University Jena | 23 |
| 4 | Lina Bezdetnaya | Centre de Recherche en Automatique de Nancy | 21 |
| 5 | Georges Wagnières | École Polytechnique Fédérale de Lausanne | 19 |
| 6 | Hubert van den Bergh | École Polytechnique Fédérale de Lausanne | 15 |
| 7 | Dietrich Scheglmann | Biolitec (Germany) | 13 |
| 8 | Alexander J. MacRobert | University College London | 9 |
| 9 | Arno Wiehe | Schott (Germany) | 9 |
| 10 | Heinrich Walt | University Hospital Zurich | 9 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| PHOTODYNAMIC THERAPY | 1993 | 389 | Nanoplatforms for cancer theranostics |
| Combining Magnetic Hyperthermia and Photodynamic Therapy for Tumor Ablation with Photoresponsive Magnetic Liposomes | 2015 | 332 | Nanoparticle-Based Drug Delivery |
| Temoporfin (Foscan<sup>®</sup>, 5,10,15,20‐Tetra(<i>m</i>‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer<sup>†,‡</sup> | 2011 | 297 | Photodynamic Therapy Research Studies |
| Assessment of Apoptosis by Immunohistochemistry to Active Caspase-3, Active Caspase-7, or Cleaved PARP in Monolayer Cells and Spheroid and Subcutaneous Xenografts of Human Carcinoma | 2008 | 250 | Cell death mechanisms and regulation |
| Temoporfin-loaded invasomes: Development, characterization and in vitro skin penetration studies | 2008 | 228 | Essential Oils and Antimicrobial Activity |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition of Temoporfin?
Which institutions lead in patent activity for Temoporfin?
What are the primary research topics associated with Temoporfin?
Who are the most prolific authors publishing on Temoporfin?
How has patent activity for Temoporfin changed in recent years?